TOSS, ANGELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.591
AS - Asia 8.414
EU - Europa 6.032
SA - Sud America 1.326
AF - Africa 256
OC - Oceania 56
Continente sconosciuto - Info sul continente non disponibili 11
Totale 29.686
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.230
SG - Singapore 2.431
CN - Cina 1.977
IT - Italia 1.760
GB - Regno Unito 1.098
VN - Vietnam 1.069
HK - Hong Kong 981
BR - Brasile 980
DE - Germania 574
SE - Svezia 555
BD - Bangladesh 433
IE - Irlanda 342
FI - Finlandia 332
RU - Federazione Russa 308
KR - Corea 277
FR - Francia 266
IN - India 248
ID - Indonesia 195
CA - Canada 182
TR - Turchia 129
UA - Ucraina 125
AR - Argentina 112
MX - Messico 111
NL - Olanda 103
IQ - Iraq 98
JP - Giappone 97
BG - Bulgaria 93
ES - Italia 76
PL - Polonia 72
ZA - Sudafrica 68
CO - Colombia 58
EC - Ecuador 57
PK - Pakistan 57
AU - Australia 51
MY - Malesia 50
EG - Egitto 48
TW - Taiwan 45
AT - Austria 44
LT - Lituania 44
AE - Emirati Arabi Uniti 39
MA - Marocco 35
VE - Venezuela 34
IR - Iran 31
PH - Filippine 30
CL - Cile 29
SA - Arabia Saudita 29
UZ - Uzbekistan 27
KE - Kenya 25
BE - Belgio 24
PY - Paraguay 24
CZ - Repubblica Ceca 20
JO - Giordania 20
NP - Nepal 18
NO - Norvegia 17
TH - Thailandia 17
AZ - Azerbaigian 16
DK - Danimarca 16
HU - Ungheria 15
IL - Israele 15
MD - Moldavia 15
SI - Slovenia 15
CH - Svizzera 14
GR - Grecia 14
TN - Tunisia 14
BO - Bolivia 13
DZ - Algeria 12
PA - Panama 12
RO - Romania 12
AL - Albania 11
CR - Costa Rica 10
DO - Repubblica Dominicana 10
HR - Croazia 10
PE - Perù 10
RS - Serbia 10
SY - Repubblica araba siriana 10
JM - Giamaica 9
KG - Kirghizistan 9
KZ - Kazakistan 8
LB - Libano 8
LV - Lettonia 8
OM - Oman 8
PT - Portogallo 8
CI - Costa d'Avorio 7
CY - Cipro 7
ET - Etiopia 7
MT - Malta 7
UY - Uruguay 7
AO - Angola 6
BH - Bahrain 6
BY - Bielorussia 6
GE - Georgia 6
EU - Europa 5
GH - Ghana 5
MK - Macedonia 5
NZ - Nuova Zelanda 5
SN - Senegal 5
XK - ???statistics.table.value.countryCode.XK??? 5
CG - Congo 4
GT - Guatemala 4
HN - Honduras 4
Totale 29.608
Salva come PNG Salva come JPEG
Città #
Ashburn 1.711
Singapore 1.413
Santa Clara 1.339
Fairfield 1.115
Hong Kong 951
Chandler 751
San Jose 735
Hefei 669
Woodbridge 536
Seattle 476
Houston 428
Southend 395
Cambridge 389
Council Bluffs 388
Beijing 363
Ho Chi Minh City 342
Dublin 337
Nyköping 336
London 331
Wilmington 331
Los Angeles 279
Dallas 266
Helsinki 260
Seoul 258
New York 255
Hanoi 248
Dearborn 212
Modena 207
Ann Arbor 206
Milan 172
The Dalles 163
Chicago 156
Jakarta 138
Lauterbourg 123
Bologna 109
San Diego 107
Jacksonville 106
Princeton 95
São Paulo 93
Munich 90
Sofia 90
Moscow 89
Boardman 82
Tokyo 82
Rome 80
Buffalo 78
Shanghai 76
Frankfurt am Main 75
Orem 73
Salt Lake City 67
Bremen 58
Eugene 52
Izmir 52
Warsaw 52
Baghdad 51
Da Nang 51
Haiphong 50
Redwood City 49
Fremont 44
Manchester 42
Montreal 40
Reggio Emilia 40
Kent 39
Nuremberg 39
Phoenix 39
Columbus 38
Dong Ket 38
Toronto 38
Johannesburg 36
Brooklyn 35
Guangzhou 35
Mexico City 35
Chennai 33
Rio de Janeiro 33
Atlanta 32
Portsmouth 32
Belo Horizonte 31
Lappeenranta 31
Parma 31
Redondo Beach 31
Stockholm 31
Denver 30
Mumbai 30
Florence 28
San Giuliano Milanese 28
Düsseldorf 27
Naples 27
Poplar 27
Dhaka 26
Turku 26
Falls Church 25
Sydney 25
Madrid 24
Miami 24
Miano 24
Tashkent 23
Vienna 23
Amsterdam 22
Brasília 22
Lawrence 22
Totale 19.392
Salva come PNG Salva come JPEG
Nome #
Cancer Treatment Induced Bone Loss (CTIBL) in breast cancer women: a multidisciplinary approach at the Modena Cancer Center screening over 600 patients. 621
A rapid genetic counselling and testing in newly diagnosed breast cancer is associated with high rate of risk-reducing mastectomy in BRCA1/2-positive italian women 483
Impressive response to dose-dense chemotherapy in a patient with NUT midline carcinoma 472
Endocrine sensitive metastatic breast cancer and bone only disease: are the new treatments always better? 453
ERBB2 mutations in hormone receptor positive primary breast cancers samples and in their matched endocrine-resistant recurrences. 417
Abstracts from the 55th European Society of Human Genetics (ESHG) Conference: Hybrid Posters 406
Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. 397
Interstitial Lung Disease in Abemaciclib-treated Patients during SARS-CoV-2 Pandemic: A Case Series. 386
Genomic alterations at the basis of treatment resistance in metastatic breast cancer: Clinical applications 365
Hereditary pancreatic cancer: A retrospective single-center study of 5143 Italian families with history of BRCA-related malignancies 362
First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis 346
Endocrine-based targeted combination versus endocrine therapy alone as first-line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trials. 343
Ovarian cancer: can proteomics give new insights for therapy and diagnosis? 339
Molecular mechanisms of PARP inhibitors In BRCA-related ovarian cancer 337
Primary and secondary prevention to effectively reduce the risk of bisphosphonate-related osteonecrosis of the jaw in patients with bone metastases . 336
Predictive role of haemoglobin on disease response to neoadjuvant chemotherapy in breast cancer. 329
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. 323
Thromboembolism (TE) and adjuvant endocrine therapy (AET) in hormone receptor positive (HR+) early breast cancer (EBC): Did the evolution of treatment change the incidence of the adverse event? A metanalysis 311
Brca detection rate in an italian cohort of luminal early-onset and triple-negative breast cancer patients without family history: When biology overcomes genealogy 307
Combined Hormonal Contraceptive Use and Risk of Breast Cancer in a Population of Women With a Family History 300
Hereditary Ovarian Cancer: Not Only BRCA 1 and 2 Genes 299
NUT midline carcinoma of the head and neck: current perspectives 295
Evaluation of Transvaginal Ultrasound plus CA-125 Measurement and Prophylactic Salpingo-Oophorectomy in Women at Different Risk Levels of Ovarian Cancer: The Modena Study Group Cohort Study 289
Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years. 288
Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat? 288
Clinical-Pathological Characteristics of HER2+ Breast Cancers patients among BRCA1/2+ carriers tested in Modena Cancer Center. 288
Reproductive risk factors in women with family history of breast cancer attending an Italian Family Cancer Clinic 287
Increasing BMI is associated with both endometrioid and serous histotypes among endometrial rather than ovarian cancers: a case-to-case study 287
Clinicopathologic Profile of Breast Cancer in Germline ATM and CHEK2 Mutation Carriers 285
CLINICAL AND PATHOLOGICAL FEATURES OF BREAST CANCER IN PATIENTS WITH SYSTEMIC SCLEROSIS: PRELIMINARY DATA FROM THE SCLERO-BREAST STUDY 284
Lifestyle intervention on body weight and physical activity in patients with breast cancer can reduce the risk of death in obese women: The EMILI study 283
Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy 281
The Association between Endometriomas and Ovarian Cancer: Preventive Effect of Inhibiting Ovulation and Menstruation during Reproductive Life 281
Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era 279
STRATEGIES TO PREDICT TREATMENT RESPONSE AND SELECT THERAPIES IN METASTATIC BREAST CANCER PATIENTS USING A NEXT GENERATION SEQUENCING (NGS) MULTI-GENE PANEL 275
Real-World Data and Clinical Implications of Next-Generation Sequencing (NGS)-Based Analysis in Metastatic Breast Cancer Patients 271
Breast ultrasonography (BU) in the screening protocol for women at hereditary-familial risk of breast cancer: has the time come to rethink the role of BU according to different risk categories? 270
Acceptability and adherence in a chemoprevention trial among women at increased risk for breast cancer attending the modena familial breast and ovarian cancer center (Italy) 269
Hereditary ovarian cancers: State of the art 268
Combined hormonal contraceptives in BRCA gene mutation carriers: why not? 265
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 259
Clinical and Pathological Features of Breast Cancer in Systemic Sclerosis: Results from the Sclero-Breast Study 253
STRATEGIES TO PREDICT TREATMENT RESPONSE AND SELECT THERAPIES IN METASTATIC BREAST CANCER PATIENTS USING A NEXT GENERATION SEQUENCING MULTI-GENE PANEL 249
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 249
The impact of reproductive life on breast cancer risk in women with family history or BRCA mutation 249
Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: To prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials 249
Twenty-years experience with de novo metastatic breast cancer 243
Characterization of new ATM deletion associated with hereditary breast cancer 242
Chemoprevention strategies for high risk women 240
Chemoprevention strategies in hereditary breast and ovarian cancer syndromes 239
Fertility and pregnancy issues in BRCA-mutated breast cancer patients 238
Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification 237
BRCA mutations among triple negative breast cancer without family history of breast and ovarian cancer: The Modena family cancer clinic experience 237
Prediction of breast and prostate cancer risks in male BRCA1 and BRCA2 mutation carriers using polygenic risk scores 236
Male Bilateral Risk-Reducing Mastectomy: Report of a Case 234
Relative and disease-free survival for breast cancer in relation to subtype: a population-based study 233
The role of exosomes in breast cancer diagnosis 233
Radiological screening programs for women at high risk of developing breast cancer 228
Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature 226
Automated capture-based NGS workflow: one thousand patients experience in a clinical routine framework 226
Endocrine therapy alone versus targeted combination strategy as first line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trial 225
Carboplatin-paclitaxel in triple-negative metastatic breast cancer during pregnancy with neoplastic thrombosis 225
Role of Intrinsic Subtype Analysis with PAM50 in Hormone Receptors Positive HER2 Negative Metastatic Breast Cancer: A Systematic Review. 219
Breast ultrasound in high-risk women 218
Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women with Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial 217
Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer: Regulatory aspects and clinical impact in Europe 217
BRCA mutation carriers' perceptions on postmenopausal hormone therapy: An Italian study 216
Association of genomic domains in BRCA1 and BRCA2 with prostate cancer risk and aggressiveness 215
Molecular characterization and targeted therapeutic approaches in breast cancer 213
Satisfaction with prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers is very high and little dependent on the participants' characteristics at surgery: a prospective study 213
EV derived miR-21 as a promising biomarker for early diagnosis and tumor activity in discrete BC subtypes: The Exobreast project 208
PARP inhibitors for the treatment of ovarian cancer 205
Molecular Pathways of Breast Cancer in Systemic Sclerosis: Exploratory Immunohistochemical Analysis from the Sclero-Breast Study 200
Thromboembolism and Adjuvant Endocrine Therapy (AET) in Hormone Receptor-Positive Early Breast Cancer (EBC): Did Treatment Evolution Change Incidence of the Adverse Event? A Meta-Analysis 194
The reduction of CA 125 serum levels in BRCA 1/2 mutation carriers after risk-reducing salpingo-oophorectomy is only partially associated with surgery: A prospective cohort, other biomarker controlled, study 194
Management of PALB2-associated breast cancer: A literature review and case report 193
Obesity in Postmenopausal Breast Cancer Patients: It Is Time to Improve Actions for a Healthier Lifestyle. The Results of a Comparison Between Two Italian Regions With Different “Presumed” Lifestyles 192
Constitutional Mosaicism: A Critical Issue in the Definition of BRCA-Inherited Cancer Risk 188
Personalized Systemic Therapies in Hereditary Cancer Syndromes 187
Adjuvant Endocrine Therapy in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer: Risk Stratification in a Real-World Setting 187
Primary fallopian tube carcinoma (PFTC) in a BRIP-1 mutation carrier: the first case report 187
Clinical-pathological features and treatment modalities associated with recurrence in DCIS and micro-invasive carcinoma: Who to treat more and who to treat less 183
COVID-related disruption in mammographic screening: a year later. 181
Occult breast cancer: the uncommon presentation of a common disease 180
PARP Inhibitors for Breast Cancer Treatment A Review 177
Cancer Predisposition Genes in Adolescents and Young Adults (AYAs): a Review Paper from the Italian AYA Working Group 172
The challenging screen detection of ovarian cancer in BRCA mutation carriers adhering to a 6-month follow-up program: results from a 6-years surveillance 171
DCE-MRI Radiomic analysis in triple negative ductal invasive breast cancer. Comparison between BRCA and not BRCA mutated patients: Preliminary results 171
BRCA mutation rate and characteristics of prostate tumor in breast and ovarian cancer families: analysis of 6,591 Italian pedigrees 170
Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores 168
Extracellular vesicles-derived miR-21 as a biomarker for early diagnosis and tumor activity in breast cancer subtypes 165
Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour 164
A 10-miRNA risk score-based prediction model for pathological complete response to neoadjuvant chemotherapy in hormone receptor-positive breast cancer 163
Safety and efficacy analysis of neoadjuvant pertuzumab, trastuzumab and standard chemotherapy for HER2–positive early breast cancer: real–world data from NeoPowER study 162
Molecular characterization as new driver in prognostic signatures and therapeutic strategies for endometrial cancer 161
LOW-FREQUENCY ALLELE VARIANTS IN NGS MULTI-GENE PANELS FOR HEREDITARY CANCER TESTING: ARTIFACTS, CHIP OR MOSAICS? MANAGING THE RESULTS IN THE LABORATORY ROUTINE 159
Automation of a capture-based NGS workflow: one thousand patients experience in a diagnostic clinical routine framework 157
Breast cancer screening of mutation carriers in the era of COVID-19 pandemic 156
The spectrum of fancm protein truncating variants in European breast cancer cases 153
Talking about sex: erectile dysfunction in the oncology patient 152
Totale 25.543
Salva come PNG Salva come JPEG
Categoria #
all - tutte 114.855
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 114.855
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021192 0 0 0 0 0 0 0 0 0 0 0 192
2021/20221.887 123 164 141 82 68 133 90 102 250 164 336 234
2022/20232.396 268 301 169 192 225 259 48 180 526 35 98 95
2023/20241.756 92 92 97 175 260 144 230 229 68 69 114 186
2024/20255.933 141 59 120 302 986 765 584 372 703 389 644 868
2025/202612.849 900 476 1.134 1.391 1.504 824 1.575 708 1.232 1.257 1.086 762
Totale 29.954